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The role of micronutrients in the risk of urinary tract 
cancer 
Tomasz Golabek1, Jakub Bukowczan2, Robert Sobczynski3, Jaroslaw Leszczyszyn4, Piotr L. Chlosta1
A b s t r a c t
Prostate, bladder and kidney cancers remain the most common urological 
malignancies worldwide, and the prevention and treatment of these dis-
eases pose a challenge to clinicians. In recent decades, many studies have 
been conducted to assess the association between supplementation with 
selected vitamins and elements and urinary tract tumour initiation and de-
velopment. Here, we review the relationship between vitamins A, B, D, and 
E, in addition to calcium, selenium, and zinc, and the risk of developing 
prostate, kidney and bladder cancer. A relatively consistent body of evidence 
suggests that large daily doses of calcium (> 2,000  mg/day) increase the 
risk of prostate cancer. Similarly, supplementation with 400 IU/day of vita-
min E carries a significant risk of prostate cancer. However, there have been 
many conflicting results regarding the effect of these nutrients on kidney 
and bladder neoplasms. Moreover, the role of other compounds in urinary 
tract carcinogenesis needs further clarification.
Key words: vitamins, elements, prostate cancer, kidney cancer, bladder 
cancer.
Introduction
Despite improvements in prostate cancer (PCa) treatment and de-
creased exposure to tobacco smoking and several occupational carcin-
ogens that cause bladder (BC) and possibly kidney cancers (KC), urinary 
tract tumours still remain the common malignancies worldwide [1–6]. 
The risk of urological neoplasms appears to be influenced by a number of 
both modifiable and non-modifiable risk factors, including age, smoking, 
obesity, physical inactivity and diet [7–14]. Of these, diet in particular 
has been the focus of a considerable amount of research. This focus is in 
part due to the increasing awareness and utilization of complementary 
and alternative medicines, a movement that resulted from the belief that 
“natural” substances are innately safe and beneficial to one’s health. 
In recent years, several studies have confirmed a significant increase in 
the consumption of vitamins, minerals and other micronutrients among 
both the general population and those who have been diagnosed with 
cancer or other chronic diseases [15–17]. Epidemiological observations 
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indicating that diets rich in fat and red or pro-
cessed meats or diets low in fibre and vegetable 
intake are associated with a higher risk of various 
neoplasms, including gastrointestinal, breast, and 
prostate cancer, have further stimulated a global 
interest in nutrition-focused strategies and inter-
ventions for tumour chemoprevention. 
Micronutrients are believed to act as pro- and 
anti-tumour risk modifiers throughout the entire 
complicated process of urogenital tumourigene-
sis. Although many studies have investigated the 
role of several vitamins and microelements in the 
aetiology and prevention of urinary tract tumours, 
disease progression, and associated complica-
tions, the results have often been conflicting or 
unclear. These conflicting results can be attributed 
to the complexity of the disease, but also to the 
lack of high quality, long term, randomised con-
trolled studies that consider important confound-
ing factors in the analyses. 
We believe that there is a  growing need for 
a  combined review and critique of the vast 
amount of information that has recently been 
published, often with inconsistent, conflicting or 
non-evidence-based advice regarding the use of 
supplements as a means to prevent urinary tract 
cancers. This article aims to review the most up-to-
date information from laboratory, epidemiological 
and clinical studies to summarize which vitamins 
and other micronutrients have shown anti-pros-
tate, -bladder, and -kidney cancer activity.
Material and methods
Our comprehensive search strategy searched 
the Medline/PubMed electronic database for arti-
cles published from the inception of the database 
until April 2014. We considered all human and an-
imal research articles that were published in En-
glish and not classified as a case report, editorial, 
comment, letter, guideline, or news. The comput-
er-based searches combined the following search 
terms related to vitamins A, B, D, E, multivitamins, 
calcium, selenium and zinc, as well as prostate, 
kidney and bladder cancer:
(i)  Terms to identify vitamin A relevant exposures:
(“Vitamin A” [Mesh] OR “vitamin a” [All Fields] 
OR “Retinoids” [All Fields] OR “retinoids” [All 
Fields] OR “Retinoic acid” [All Fields] OR “retino-
ic acid” [All Fields] OR “Carotenoids” [All Fields] 
OR “carotenoids” [All Fields] OR “β-Carotene” [All 
Fields] OR “β-carotene” [All Fields] OR “Beta-car-
otene” [All Fields] OR “beta-carotene” [All Fields] 
OR “Provitamin A” [All Fields] OR “provitamin A” 
OR “Xanthophylls” [All Fields] OR “xanthophylls” 
[All Fields [Mesh]).
(ii)  Terms to identify vitamin B relevant exposures:
(“Vitamin B” [Mesh] OR “vitamin B” [All Fields] 
OR “Vitamin B complex” [All Fields] OR “vitamin B 
complex” [All Fields] OR “Folic acid” [All Fields] OR 
“folic acid” [All Fields] OR “Folate” [All Fields] OR 
“folate” [Mesh]).
(iii)  Terms to identify vitamin D relevant expo-
sures:
(“Vitamin D” [Mesh] OR “vitamin d” [All Fields] 
OR “25-hydroxyvitamin D” [All Fields] OR “25(OH)D” 
[All Fields] OR “Calcidiol” [All Fields] OR “cal-
cidiol” [All Fields] OR “Ergocalciferol” [All Fields] 
OR “ergocalciferol” [All Fields] OR “Cholecalcif-
erol” [All Fields] OR “cholecalciferol” [All Fields] 
OR “1α,25-dihydroxyvitamin D3” [All Fields] OR 
“1,25-Dihydroxyvitamin D” [All Fields] OR “1,25-di-
hydroxyvitamin D” [Mesh]).
(iv) Terms to identify vitamin E relevant exposures:
(“Vitamin E” [Mesh] OR “vitamin e” [All Fields] 
OR “Tocochromanols” [All Fields] OR “tocochro-
manols” [All Fields] OR “Tocotrienol” [All Fields] 
OR “tocotrienol” [All Fields] OR “Tocopherols” [All 
Fields] OR “tocopherols” [Mesh]).
(v)  Terms to identify multivitamin and micronutri-
ent relevant exposures:
(“Vitamins ” [Mesh] OR “vitamins” [All Fields] 
OR “Multivitamin” [All Fields] OR “multivitamin” 
[All Fields] OR “Multivitamins” [All Fields] OR “mul-
tivitamins” [All Fields] OR “Multivitamin-mineral” 
[All Fields] OR “multivitamin-mineral” [All Fields] 
OR “Multivitamin-multimineral” [All Fields] OR 
“multivitamin-multimineral” [All Fields] OR “Micro-
nutrients” [All Fields] OR “micronutrients” [Mesh]).
(vi) Terms to identify calcium relevant exposures:
(“Calcium” [Mesh] OR “calcium” [All Fields] OR 
“CA” [All Fields] OR “Ca” [All Fields] OR “Calcium 
compounds” [All Fields] OR “calcium compounds” 
[Mesh]).
(vii)  Terms to identify selenium relevant expo-
sures:
(“Selenium” [Mesh] OR “selenium” [All Fields] 
OR “SE” [All Fields] OR “Se” [All Fields] OR “Sele-
nium compounds” [All Fields] OR “selenium com-
pounds” [Mesh]).
(viii) Terms to identify zinc relevant exposures:
(“Zinc” [Mesh] OR “zinc” [All Fields] OR “ZN” [All 
Fields] OR “Zn” [All Fields] OR “Zinc compounds” 
[All Fields] OR “zinc compounds” [Mesh]).
(ix) Terms to identify relevant outcomes:
(“urinary tract cancer” [Mesh] OR “urinary 
tract cancers” [All Fields] OR “prostate cancer” 
[All Fields] OR “prostatic cancer” [All Fields] OR 
“prostatic neoplasm” [All Fields] OR “prostate neo-
plasm” [All Fields] OR “cancer of the prostate” [All 
Fields] OR “cancer of prostate” [All Fields] OR “kid-
ney cancer” [All Fields] OR “kidney neoplasm” [All 
Fields] OR “cancer of the kidney” [All Fields] OR 
“cancer of kidney” [All Fields] OR “bladder cancer” 
[All Fields] OR “bladder neoplasm” [All Fields] OR 
“cancer of the bladder” [All Fields] OR “cancer of 
bladder” [Mesh]). 
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Parts i–viii were combined with part ix using 
“AND” to search MEDLINE.
Results
The search strategy identified 32,327 articles 
about micronutrients and urinary tract tumours. 
After an initial screening based on titles and ab-
stracts, a total of 218 papers remained for further 
evaluation. 
Discussion
Vitamin A 
Vitamin A is a generic term for a family of re-
lated compounds consisting of retinol and its 
derivatives, the retinoids [18]. Moreover, about 
50 different carotenoids are viewed as pro-vi-
tamin A  compounds, meaning they can be con-
verted to various forms of vitamin A, including 
retinol, retinal or retinoic acid [19]. Preformed 
vitamin A  (retinol and retinyl esters) is found in 
cod liver oil, butter, eggs, animal products, and 
fortified grains, whereas provitamin A carotenoids 
are found in highly pigmented vegetables such as 
carrots, squash, and green leafy vegetables [18]. 
Vitamin A and its derivatives play many important 
roles in the human body but primarily are involved 
in both normal and cancerous cell differentiation 
[19]. Moreover, these molecules are required for 
appropriate organogenesis and are involved in the 
maintenance of epithelial tissues and immune 
function, in addition to mediating vision [18]. In 
addition, vitamin A has been shown to have sev-
eral anticancer activities [19]. These activities 
are thought to rely on the antioxidant activities 
of vitamin A  (carotenoids are involved in the 
scavenging of two types of reactive oxygen spe-
cies), increases in the expression and function of 
a number of antioxidant and detoxifying enzymes 
(carotenoids and retinoids), and the proapoptotic 
effect of these molecules (carotenoids and reti-
noids) [18, 19].
Data from the most recent research suggest 
that the consumption of vitamin A  and its ana-
logues may lower the risk of developing kidney 
and bladder cancers. The supporting evidence 
is not, however, unambiguous [20]. Studer et al. 
used a  prospective, randomized, multicenter tri-
al to evaluate the effects of synthetic retinoid – 
etretinate in 90 patients diagnosed with stage Ta 
and T1 superficial papillary bladder tumours who 
underwent transurethral resection of the tumour 
[21]. Although the time to first recurrence was 
similar in both arms of the study, the mean inter-
val to subsequent BC recurrence was significant-
ly longer in patients taking vitamin A analogues 
(20.3 months vs. 12.7 months, p < 0.006). Simi-
larly, the number of transurethral resections per 
patient per year was also significantly reduced in 
men and women taking the adjuvant etretinate. 
The authors concluded that retinoids could have 
a potential use in the primary but not secondary 
prevention of kidney and bladder cancers. Vita-
min A plays a crucial role in maintaining normal 
physiology in the human body. In excess, however, 
this vitamin is highly toxic, causing fever, hypoten-
sion and respiratory failure. Because of these side 
effects and the absence of any positive results, 
the National Bladder Cancer Collaborative Group 
Study had to be terminated. This clinical trial 
aimed to prove that 13-cis-retinoic acid could po-
tentially be used as a chemoadjuvant treatment in 
patients at high risk of recurrent Ta and T1 blad-
der cancer [22]. The novel retinoids appear to be 
free of any serious side effects. These molecules 
could, therefore, be considered in bladder cancer 
prevention, provided that the daily recommended 
dosage is not exceeded. 
There are no definitive data on the effect of vi-
tamin A in prostate cancer pathogenesis. Neither 
observational nor epidemiological studies of the 
pure form of vitamin A could provide clear-cut an-
swers [23]. However, the authors of the latest and 
also largest study investigating the role of vitamin A 
in prostate cancer aetiology prospectively anal-
ysed the serum retinol concentration of 22,000 
men over the course of three years [24]. The re-
sults showed that the men with higher serum reti-
nol concentrations prior to the study had a greater 
risk of cancer. The authors noted the same rela-
tionship between serum retinol concentration and 
the risk of developing a more aggressive form of 
cancer. Although the exact mechanisms underly-
ing carcinogenesis under the observed conditions 
are not yet known, it is still possible that retinol 
may stimulate carcinogenesis in the prostate 
through sex hormones or cell membrane modifi-
cations.
Calcium and vitamin D
Calcium (Ca) is the most important nutrient in 
the diet because it is a  structural component of 
bones, teeth, and soft tissues [25, 26]. Moreover, 
calcium is essential in many of the body’s meta-
bolic processes because it serves as a second mes-
senger, transmitting signals between the plasma 
membrane and the intracellular machinery. The 
Ca2+ ion is involved in vital cellular processes in-
cluding contraction, secretion, the induction and 
regulation of apoptosis, and the regulation of cell 
proliferation and differentiation [26]. In addition, 
extracellular calcium is a cofactor for clotting fac-
tors and adhesion molecules [25]. Dietary sources 
of calcium include dairy products, various leafy 
vegetables, and calcium-fortified foods [25, 26]. 
The  current recommended daily intake of calci-
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um is 1000 mg/day for men aged 19 to 70 years 
and 1,500 mg/day for men > 70 years of age [27]. 
Calcium supplementation is not, however, free of 
risk. Some epidemiological data suggest that in-
gesting excess calcium from food and dietary sup-
plements can increase the overall risk of prostate 
cancer. Similarly, the results of a  meta-analysis 
that included 11 observational studies indicated 
that daily milk intake positively correlated with 
the risk of developing prostate cancer in the fu-
ture [28]. A summary that pooled 37 prospective 
cohort studies and 4 interventional studies, all of 
which examined the effects of diet in prostate 
cancer and were published between 1966 and 
2003, found a positive link between a high calci-
um intake (> 2,000 mg/day) and the increased risk 
of prostate cancer [29]. Gao et al. also confirmed 
these conclusions in their prospective study on 
men with high dairy and calcium intakes who 
were at increased risk of developing prostate can-
cer in the future [30]. 
The mechanisms underpinning these associa-
tions could be explained by the relationship be-
tween calcium and vitamin D. Too much calcium 
in the diet can subsequently reduce 1,25(OH)2 
vitamin D levels,  which in turn enhances neo-
plastic cell de-differentiation and promotes the 
development of a more aggressive cancer. More-
over, this form of vitamin D has previously been 
shown to harbour anti-proliferative and anti-met-
astatic properties [31]. The Health Professionals 
Follow-up Study confirmed the role of calcium-vi-
tamin D balance in prostate cancer aetiology [32]. 
An analysis of the medical records of 47,750 men 
revealed that dietary and supplemental calcium 
intake is an independent risk factor for develop-
ing prostate cancer. Additionally, a  daily calcium 
intake of more than 1,500 mg a day is associated 
with more aggressive cancers (Gleason > 7). It is 
worth mentioning that some authors could not 
confirm the carcinogenic effects of large amounts 
of dietary calcium in their studies. In those re-
ports, however, daily calcium intake did not ex-
ceed 1,300 mg/day [30, 33].
Vitamin D refers to two fat-soluble substanc-
es, vitamin D3 (cholecalciferol) and vitamin D2 
(ergocalciferol), and their metabolites, which are 
considered important nutrients for human health 
[34]. Vitamin D is primarily produced by sun-ex-
posed skin. Vitamin D is also absorbed by the gas-
trointestinal tract (mainly from dairy products, 
eggs and oily fish) to a much lesser degree, and 
vitamin D deficiency is a common finding in many 
men. Vitamin D exerts a spectrum of biological ef-
fects. This vitamin is the precursor of the potent 
steroid hormone calcitriol, which regulates calci-
um and phosphate metabolism and is essential 
for bone mineralization [35]. Moreover, vitamin D 
has important homeostatic functions in fetal and 
adult development and in the differentiation of 
the endocrine, metabolic, neurological, epidermal, 
and immunological systems [34]. In addition, vita-
min D plays a role in regulating the mechanisms 
controlling cell proliferation, differentiation, and 
growth, and may inhibit neoplastic cell cycle pro-
gression and tumour cell growth in addition to 
regulating the initiators of cellular angiogenesis 
in several cancer cell lines, including colonic cells 
from colorectal tumours, head and neck squa-
mous cell carcinomas, and prostate and breast 
cancer cell lines [34]. Proper sun exposure may be 
protective against some types of neoplasms, such 
as digestive system cancers, and ovarian, breast, 
and cervical tumours [36]. However, the epide-
miological results investigating the link between 
sun exposure and prostate cancer risk have been 
inconclusive thus far. A  number of studies have 
reported an inverse correlation between sun ex-
posure levels and both prostate cancer incidence 
[37–39] and mortality [40, 41]. On the other hand, 
ecological evidence from the U.S. has suggested 
that exposure to high levels of solar ultra-violet 
radiation is associated with an increased risk of 
PCa mortality [42]. Moreover, findings from the 
Prostate Testing for Cancer and Treatment (Pro-
tecT) study demonstrated a reduced risk of both 
advanced cancer and high Gleason grade in men 
with PCa who spent less time outside over the 
course of their life, indicating low exposure to 
sunlight [43]. 
The link between dietary vitamin D and pros-
tate cancer still remains inconclusive and unclear. 
A meta-analysis of six observational studies exam-
ining the relationship between vitamin D intake 
and prostate cancer risk found no such association 
[44]. However, the daily vitamin D intake of five 
out of six studies was below the recommended 
400 IU per day for adults aged over 50 years (rang-
ing from 132 to 376 IU/day). Therefore, the true 
effects of dietary vitamin D on the prostate cancer 
risk could not have been determined by this study. 
Additionally, a  recent meta-analysis by Gilbert et 
al. that scrutinized 25 prospective cohort/nested 
case-control or case-control studies examining the 
associations between vitamin D (dietary intake, 
circulating 25-hydroxy-vitamin-D (25(OH)D), and 
1,25-dihydroxy-vitamin-D (1,25(OH)2D)) concen-
trations and prostate cancer found little evidence 
to support a major role of vitamin D in preventing 
PCa incidence or progression [45]. There was no 
evidence of any association between dietary vita-
min D intake and the risk of aggressive prostate 
cancer, and weak statistical evidence of a positive 
relationship with the total PCa risk was only ob-
served if the meta-analysis was restricted to co-
hort/nested case-control studies only. Moreover, 
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neither 25(OH)D nor 1,25(OH)2D was associated 
with total or aggressive prostate cancer risk or to-
tal PCa risk, respectively. The authors did observe 
some weak evidence of a  small decrease in the 
risk of aggressive PCa with increasing 1,25-dihy-
droxy-vitamin-D levels. However, these findings 
were only based on two studies. 
Interesting observations were generated by the 
ASCENT study, in which hormone-resistant pros-
tate cancers were treated with a new form of oral 
vitamin D (DN-101) in addition to docetaxel che-
motherapy [46]. Although the results showed no 
statistically significant decrease in prostate-spe-
cific antigen (PSA) in the vitamin D treatment 
group, the total survival rate in this group was 
significantly higher than the survival rate of the 
docetaxel only group. Moreover, DN-101 did not 
increase docetaxel-related toxicity. Vitamin D me-
tabolism takes place primarily in the kidney, and 
one would expect an association between any 
kidney pathology, including cancer, and abnormal 
vitamin D levels. An inverse link between solar ul-
traviolet-B radiation and the risk of renal cell car-
cinoma (RCC) was demonstrated in a global eco-
logical study [47]. However, the prospective study, 
which examined 25(OH) vitamin D levels in 775 pa- 
tients with RCC, produced conflicting results, 
showing no link between the two variables [48]. 
Moreover, two additional prospective and two 
case-control studies failed to show that vitamin D 
could be linked with RCC pathogenesis [49–52]. 
The results should be interpreted with caution, 
however, as these studies had major design limita-
tions, were generally underpowered, and did not 
include any information with regards to vitamin D 
derived from sun-exposed skin. Studies exploring 
the link between genetically determined vitamin D 
receptor polymorphisms and RCC support the hy-
pothesis that vitamin D may somehow be associ-
ated with RCC pathogenesis [53, 54]. Vitamin D 
also seems to be linked with urothelial carcinoma 
of the bladder (UCB), as vitamin D receptors are 
expressed in BC tissues [55]. Interesting results 
from Konety et al. indicated that vitamin D has 
chemopreventive effects in bladder cancer [56]. 
In this study, the early installation of intravesical 
calcitriol in rats previously exposed to a carcino-
gen was associated with lower cancer burden and 
a  less aggressive form of cancer. Thus far, only 
two studies have examined vitamin D status, as 
measured by serum 25-hydroxy-vitamin-D con-
centration, and risk of human bladder cancer [57, 
58]. The Alpha-Tocopherol, Beta-Carotene Cancer 
Prevention (ATBC) Study, which was a randomised 
controlled trial conducted to determine the ef-
fects of α-tocopherol and β-carotene supplements 
on cancer incidence in male smokers, found that 
lower serum 25(OH)D levels were associated with 
a  nearly 2-fold increased risk of UCB compared 
to higher serum 25(OH)D levels [59]. In contrast, 
the Prostate, Lung, Colorectal, and Ovarian (PLCO) 
Cancer Screening Trial found no evidence of an 
association between vitamin D level and risk of 
bladder cancer [58]. The difference between the 
results in these trials may be explained by the in-
clusion of women and non-smokers in the PLCO 
study.
Selenium and vitamin E
Vitamin E is a collective term given to a group 
of four tocopherols and four tocotrienols [59]. 
The richest dietary sources of vitamin E are nuts, 
seeds, vegetable oils, green leafy vegetables and 
fortified cereals [60]. All of the tocopherols and 
tocotrienols are potent antioxidants with lipop-
eroxyl radical-scavenging activities, while spe-
cific forms of vitamin E have anti-inflammatory 
effects [59]. Because of these properties, g- and 
D-tocopherols have been proposed as potential-
ly useful chemopreventive agents. Experimental 
studies have shown that these molecules have 
an inhibitory effect on moderate colitis-promot-
ed colon carcinogenesis and prostate cancer 
cell growth in athymic mice [59, 61]. Similarly, 
results from the ATBC suggested that vitamin E 
might carry chemopreventive properties [62]. This 
study showed a  32% decrease in the incidence 
of prostate cancer and a 41% decrease in pros-
tate cancer-related mortality in men who received 
50 mg of α-tocopherol daily for 5 to 8 years. An-
other study only reported a  reduced incidence 
of advanced prostate cancer in the smoker sub-
group [63]. 
Selenium (Se) is a trace element that occurs in 
both organic and inorganic forms. Selenium can 
be found in nuts, fish, chicken, beef, cereal, and 
eggs. Se contributes to human health by promot-
ing proper enzyme function, proper redox func-
tion, and other effects on the immune response. 
This mineral also possesses antioxidant and can-
cer fighting properties, including the inhibition of 
cell proliferation, the induction of apoptosis and 
the modulation of immune function [64]. The an-
ticancer effect of selenium was confirmed in both 
in vitro and in animal studies. In prostate cancer, 
this effect is mediated by the dose- and time-de-
pendent inhibition of cancer cell growth and the 
induction of apoptosis in human PC3 prostate 
cancer cells [65]. In addition, selenium exhibits 
antiproliferative and antiangiogenic effects [66, 
67]. Some epidemiologic data suggested that Se 
may have a protective role and may also reduce 
prostate cancer cell growth. The Nutritional Pre-
vention of Cancer Trial (NPC) reported a 50% lower 
incidence of prostate cancer in men who received 
200 ng of supplemental selenium daily [68]. The 
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SELECT study, in turn, examined the effect of 
oral selenium (200 µg/day from L-selenomethio-
nine) with or without vitamin E (400 IU/day of 
all-rac-α-tocopheryl acetate) in 35,533 men over 
the course of 7 to 12 years [69]. The initial results 
were published after 5.5 years of follow-up and 
found no reduction in the risk of prostate cancer 
with either selenium or vitamin E supplements. 
However, after extending the follow-up period by 
another 2 years, the authors proved that vitamin E 
supplementation carried a statistically signifi-
cant risk of prostate cancer [70]. Interestingly, the 
majority of the detected neoplasms had low-risk 
characteristics. The differences in the results of 
the SELECT and the Alpha-Tocopherol, Beta-Caro-
tene Cancer Prevention Study may be attributed 
to the fact that all of the men in the ATBC study 
were long-term smokers, prostate cancer was not 
a  primary end point, and the participants were 
not screened for PCa, with the result that the dis-
ease was detected at more advanced stages than 
in the SELECT study. In addition, the ATBC was 
designed and analysed as a factorial trial, so the 
reported effect of vitamin E was estimated across 
the effect of β-carotene [62, 70].
In the SELECT study, the role of selenium sup-
plementation in the prevention of primary pros-
tate cancer could not be ascertained. Because 
the increased risk of PCa in the vitamin E and 
selenium combination group was not statistically 
significant, a potential protective effect of Se (in 
which Se decreases the increased risk associat-
ed with vitamin E alone) needs to be considered. 
On the other hand, no benefit was observed in 
men taking oral selenium only. Similarly, recent 
results from the Negative Biopsy Trial, a  Phase 
3, randomised, double-blind, placebo-controlled 
clinical trial, investigating the effect of selenised 
yeast supplementation on the incidence of pros-
tate cancer in men at high risk for PCa, found no 
effect of selenium supplementation during 5 years 
of follow-up [71].
With regards to the role of selenium in prostate 
cancer incidence, the differences in the findings 
from the NPC and the SELECT studies could well 
be explained by the insufficient Se levels in the 
NPC cohort as opposed to normal selenium levels 
in the SELECT study group [68–70]. 
It has been widely postulated that low body se-
lenium stores increase the risk of cancer and that 
cancer itself can in turn cause low selenium levels. 
This hypothesis has been indirectly extrapolated 
from the study by Kwiatek et al. [72]. This group 
found greater Se concentrations in renal cancer 
compared to healthy kidney tissues. A  recent 
study from Germany evaluated the link between 
selenium and renal cancer [73]. The study group 
consisted of 41 cancer patients and the control 
group contained 21 patients; the study measured 
the serum selenium and selenoprotein P (SePP) 
levels of both groups. SePP serves as the major 
Se transport protein in the blood and is a reliable 
biomarker of selenium status in marginally sup-
plied individuals. The results of the study showed 
that a higher tumour grade and tumour stage at 
diagnosis correlated with lower SePP and Se con-
centrations. Moreover, a low Se status at diagno-
sis (SePP < 2.4 mg/l) was associated with a worse 
5-year survival rate (20%). These findings sug-
gest that both Se and SePP concentrations have 
a prognostic and possibly preventive value in RCC. 
Further prospective studies are therefore highly 
valuable. 
The role of selenium in bladder cancer aetiol-
ogy is far from obvious. However, new evidence 
has recently emerged from epidemiological data. 
These data support a potential preventive role of 
selenium against bladder cancer [74]. The latest 
meta-analysis, which pooled 7 published studies 
encompassing a  total of 1,910 cancer patients 
and 17,339 control patients, estimated that the 
total cancer incidence was greater in patients with 
low serum selenium concentrations. The protec-
tive effect of this trace element was only observed 
in women. This finding could possibly be attribut-
ed to sex-specific Se accumulation and excretion. 
However, a  meta-analysis of studies examining 
selenium supplementation and the risk of primary 
bladder cancer, its incidence and mortality pro-
duced contrasting results [75]. This study revealed 
protective effects of Se that were only observed 
in men. 
Vitamin E has been noted to have a  similar 
link with bladder cancer. The available support-
ing evidence is inconsistent and shows no clear 
association. The Danish Diet Cancer and Health 
Study supports a protective effect of dietary, but 
not supplemental, β-carotene on bladder cancer 
[76]. This study included 55,557 men and women 
aged 50–64 years at the commencement of the 
study who had no previous diagnosis of cancer. 
The data were collected through the completion 
of a  detailed food frequency questionnaire that 
included information on the consumption of vi-
tamins C, E, folate, and β-carotene from both the 
diet and supplements. For a median of 10.6 years 
of follow-up, no association between vitamin E 
and bladder cancer was found. However, the Can-
cer Prevention Study II, which analysed 991,522 
adult Americans, found that 10 years of regular 
vitamin E supplementation resulted in lower blad-
der cancer-related mortality rates [77]. However, 
this chemoprotective effect was not seen when vi-
tamin E was taken for less than 10 years. A further 
sub-analysis of the SELECT study, which evaluated 
34,887 men taking selenium or vitamin E or se-
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lenium with vitamin E for 7.1 years, was recently 
published [78]. This analysis did not confirm the 
protective role of selenium or vitamin E in lower-
ing bladder cancer risk. 
Preclinical studies have shown that vitamin E 
reduces the risk of renal cancer in both men and 
women [79]. This finding was also supported by 
the Iowa Women’s Health Study [64] and an Italian 
case-control study [48]. Larger case-control studies 
could not, however, confirm previously observed 
results [80, 81]. Before vitamin E supplementation 
is recommended as a primary preventive measure 
against cancers, one should also consider the re-
sults of a meta-analysis by Miller et al. [82]. This 
study pooled data from 135,967 patients from 
19 clinical studies, showing increased mortality 
rates in both men and women taking ≥ 400 IU/day 
of vitamin E. Thus, based on the currently avail-
able evidence, the widespread use of tocopherol 
supplements in urologic cancer prevention cannot 
be safely recommended.
B vitamins 
Vitamin B is a family of water soluble substanc-
es found in many foods, particularly citrus fruits, 
leafy green vegetables, cruciferous vegetables, 
cereals, and liver [83]. Several studies have pos-
tulated a link between the metabolism of specif-
ic forms of vitamin B and carcinogenesis. Folate 
(naturally occurring vitamin B9), B
12 and B6 are 
involved in a one-carbon metabolic pathway nec-
essary for both cell proliferation and gene expres-
sion [84]. Historically, carcinogenesis was thought 
to primarily arise from de novo DNA mutations. 
Recently, however, epigenetic mechanisms that 
alter gene expression without affecting the DNA 
sequence have attracted increasing attention as 
playing an equal or even greater role in cancer 
development and progression. The role of B vita-
min-mediated DNA methylation in carcinogenesis 
has been increasingly recognised as a novel tar-
get in cancer chemoprevention. The availability 
of methyl groups is largely dependent on serum 
folate levels, which provide methyl groups for ho-
mocysteine-methionine conversion in the form of 
5-methyltetrahydrofolate. This reaction is cata-
lysed by a vitamin B
12-dependent enzyme. In ef-
fect, methionine becomes S-adenosyl methionine, 
a potent and universal methyl donor that partici-
pates in various biochemical processes, including 
DNA methylation [85]. Additionally, folate may 
play a  protective role in cancer development by 
promoting the synthesis of thymidylate from ura-
cil, lowering the chances of double-strand breaks 
due to the mis-incorporation of uracil and also en-
suring the appropriate mismatch repair. 
Global DNA hypomethylation with gene-specif-
ic hypermethylation is one of the most common 
epigenetic patterns observed in the development 
and progression of numerous tumours, includ-
ing prostate cancer. In the prostate, the methyl-
ation-induced silencing of tumour suppressor 
genes appears to be the driving force in cancer 
development [86]. Interestingly, both a  deficien-
cy and excess of one-carbon nutrients have been 
hypothesised to increase prostate cancer risk [85, 
87, 88]. This observation has been suggested by 
conflicting results from epidemiological research 
and may reflect a  possible dual role of folate in 
prostate carcinogenesis [85, 89, 90]. Low folate 
levels were observed in murine prostate cancer 
models [91]. Conversely, folate deficiency stopped 
the progression of pre-existent prostate cancer in 
murine models, and high serum folate levels were 
associated with an increased progression rate in 
patients with existing prostate cancer [87, 92]. Be-
cause several countries fortify foods with folate, 
a better understanding of the true effects of folate 
in prostate cancer development and progression 
is necessary to inform appropriate dietary recom-
mendations [93]. The effect of folate on prostate 
carcinogenesis can be confounded by alcohol con-
sumption and the C677T polymorphism of the 
methylenetetrahydrofolate reductase (MTHFR) 
gene. Heavy alcohol intake may carry a higher risk 
for prostate cancer [94]. Of the previous epidemi-
ological studies which controlled for alcohol con-
sumption, only four assessed the interaction be-
tween folate and alcohol intake, with inconsistent 
results [90, 95, 96]. A Swedish population-based 
study of 254 men diagnosed with prostate cancer 
found that higher plasma levels of vitamin B
12 and 
folate were associated with up to 3-fold greater 
prostate cancer risk, suggesting that vitamin B12 
and folate may stimulate prostate cancer devel-
opment [86]. A British population-based case-con-
trol study, systematic review and meta-analysis 
that measured the plasma concentrations of PSA, 
folate and vitamin B12 in 1,461 men aged 50–69 
years reported a significantly higher risk of pros-
tate cancer in men with higher B12 and folate plas-
ma levels [87]. In contrast, a Canadian case-control 
study from 2012 that analysed plasma PSA and 
assessed dietary B vitamin intake through the use 
of a  questionnaire did not confirm the findings 
from the previous studies, instead finding that 
folate and vitamins B2, B6, and B12 were not asso-
ciated with prostate cancer risk. The study found 
that alcohol consumption was associated with in-
creased prostate cancer risk, which was higher in 
men with low folate intake and even more so in 
those with the CC MTHFR genotype [97]. Similarly, 
a recent case-control study from the US compared 
plasma PSA levels with questionnaire-estimated 
dietary folate, B6 and B12 intake in 144 prostate 
cancer patients and found no association between 
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B vitamin intake (folate, B12 and B6) and prostate 
cancer risk. The study was, however, limited by 
its small sample size [98]. The most recent large-
scale, population-based case-control study from 
Norway analysed serum folate and B
12 concen-
trations in 3,000 prostate cancer patients, finding 
that high serum folate levels may be associated 
with a greater risk of prostate cancer [99]. How-
ever, the study did not find a positive correlation 
between serum B
12 levels and PCa risk. 
Zinc
Zinc is an essential mineral that acts as a co-
factor for more than seventy enzymes. A well-bal-
anced diet provides, on average, 11 mg of zinc 
per day. Zinc is primarily derived from meat, nuts, 
vegetables and zinc supplements. The hypoth-
esis suggesting that zinc plays a  protective role 
against prostate cancer was first described in 
studies showing that zinc levels were significant-
ly lower in men with prostate cancer. Other trials 
also reported that zinc might halt cancer growth 
and invasion [64, 100]. However, the Health Pro-
fessionals Follow-up Study reported a significantly 
higher rate of prostate cancer in men taking over 
100 mg of zinc daily for 10 years [101]. These men 
also had a greater risk of developing advanced and 
metastatic forms of the neoplasm. These results 
are supported by the latest Italian observational 
study, which also noted this harmful cause-and-
effect relationship [102]. The question of wheth-
er consuming large amounts of zinc in one’s diet 
(with or without the use of supplements) increases 
the risk of prostate cancer has yet to be answered. 
The role of zinc in bladder cancer has not been 
well examined. Patients suffering from urothelial 
bladder carcinoma were found to have lower se-
rum zinc levels [8]. Additionally, the authors of this 
study reported significantly lower levels of zinc in 
bladder cancer tissue as compared with healthy 
tissues. Hong et al. proved that a zinc-citrate com-
pound has an anticancer effect (through the in-
duction of apoptosis) in bladder cancer cells [103]. 
Zinc has also been investigated in patients 
with kidney cancer. A  group of researchers from 
Belgium evaluated Zn and metallothionein (MT) 
levels in non-neoplastic and neoplastic kidney tis-
sues from patients with urothelial carcinoma or 
adenocarcinoma [104]. The authors of this study 
found that zinc and metallothionein levels were 
lower in renal tumour tissues than healthy tissues 
from the same kidney. Kwiatek et al. confirmed 
these findings [72], noting significantly lower 
zinc concentrations in kidney cancer tissues than 
non-cancerous kidney tissues.
This observation may possibly reflect cancer 
activity. A  study investigating a possible link be-
tween zinc and telomerase, an enzyme responsi-
ble for the unlimited proliferation of cancer cells, 
found that zinc enhances telomerase activity in 
human renal cells, which may suggest an indirect 
role of zinc in promoting uncontrollable RCC cell 
proliferation [105]. 
Multivitamins
Multivitamins are the most frequently used 
over-the-counter dietary supplements [15]. Fifty 
percent of Americans regularly take dietary sup-
plements, spending over $20 billion annually for 
this purpose alone [16]. The motivation for the 
use of multivitamins varies, but is often fuelled by 
product health claims suggesting that these prepa-
rations will prevent chronic diseases and cancer 
[17]. The hypothesis that multivitamins may lower 
the chance of developing cancer has been derived 
from studies indicating that a  diet rich in fruits 
and vegetables is associated with a lower risk of 
cardiovascular disease and cancer. Multivitamins 
contain the micronutrients classified as essential 
by the Institute of Medicine, which is why their 
use can be recommended to people with poor di-
ets [106]. Of the numerous observational reports 
examining the association between supplement 
use and the risk of developing disease, only a few 
have specifically studied the use of multivitamins. 
The data on the association between the use of 
multivitamins and prostate cancer risk are predom-
inantly derived from a meta-analysis and two large 
randomised clinical trials [107–109]. These studies 
followed the publication of results from the large 
Case-Control Surveillance Study by Zhang et al. 
in 2009, which revealed that the long-term use of 
zinc-free multivitamins was not associated with 
an increased risk of prostate cancer in the 1,706 
prostate cancer cases studied [110]. Subsequent-
ly, Stratton and Godwin conducted a  systematic 
review and meta-analysis of all available data on 
this subject in 2011, assessing the effect of sup-
plemental vitamins and minerals on prostate can-
cer risk, disease severity and cause-specific death 
[107]. None of the evidence suggested that the use 
of multivitamins affected the incidence or severity 
of prostate cancer. Although additional sensitivity 
analyses were conducted, no associations were 
found. Similarly, the Physicians’ Health Study II, 
a  large, randomised, double-blind, placebo-con-
trolled trial of 14,641 male US physicians aged 
≥ 50 years, found no significant effect of multivi-
tamin use on prostate cancer risk [108]. The most 
recent systematic review of double-blind, place-
bo-controlled, randomised clinical trials also does 
not support the hypothesis that dietary supple-
ments are effective treatments for men suffering 
from prostate cancer [109].
The evidence suggesting that multivitamins 
reduce the risk of bladder cancer while increasing 
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the risk of non-Hodgkin lymphoma is limited and is 
derived from case-control and cohort studies [111]. 
Conflicting observations arose from an analysis of 
161,808 postmenopausal women from the Wom-
en’s Health Initiative clinical trial, which found that 
41.5% of all participants used multivitamins [15]. 
After medians of 8.0 and 7.9 years of follow-up in 
the clinical and observational cohorts, respective-
ly, 9,619 neoplasms, including kidney and bladder 
cancers, were reported. However, multivariate-ad-
justed analyses found no correlation between mul-
tivitamin use and kidney and bladder cancer risk. 
The more recent VITamins And Lifestyle (VITAL) 
study from the US additionally confirmed that the 
long-term use of multivitamins did not reduce the 
risk of bladder cancer [112]. Three hundred and 
thirty incident urothelial cancers were found in 
the 77,050 eligible VITAL study participants after 
6 years of follow-up. None of the studied multivi-
tamins, mineral or anti-inflammatory supplements 
were significantly linked with bladder cancer risk in 
age-adjusted or multivariate analyses. 
Conclusions
Patients with urological cancers, researchers 
and clinicians are faced with voluminous and of-
ten conflicting advice regarding nutritional sup-
plementation. Any advice to the patients must be 
guided by the fact that there is no definite proof 
that any of the discussed micronutrients can im-
pact the course of prostate, bladder or kidney neo-
plasms. Much of the data reviewed in this report 
were found in studies that showed significant 
diversity in presentation, methodology and tech-
nique. Moreover, other elements, such as absorp-
tion rates, transportation, metabolic pathways, 
and genetic and epigenetic factors could have 
further affected the reported outcomes. Although 
studies on micronutrients and urological cancer 
have been inconclusive, there is a  relatively con-
sistent body of evidence showing that large doses 
of calcium taken daily (> 2000 mg/day) increase 
the risk of prostate cancer. Similarly, 400 IU/day 
of vitamin E supplementation carries a significant 
risk of PCa. However, there is no strong evidence 
for any beneficial or negative effect of vitamins A, 
B, D, selenium or zinc on prostate cancer. Similarly, 
the relationship between vitamins, zinc, seleni-
um, and calcium and the incidence of renal and 
bladder malignancies remains unclear. Additional 
well-designed intervention studies investigating 
the potential association between micronutrients 
and prostate, kidney and bladder neoplasms and 
the underlying mechanisms of action are needed, 
especially considering that the incidence of uri-
nary tract tumours is likely to continue increasing 
as a result of global population aging.
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